- Home
- DBCA vs ABSI Comparison
DBCA vs ABSI Comparison
Compare DBCA & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$5.60
Company Overview
Basic Information| Metric | DBCA | ABSI |
|---|---|---|
| Founded | 2025 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 427.3M | 357.9M |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DBCA | ABSI |
|---|---|---|
| Price | $9.88 | $5.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.96 |
| AVG Volume (30 Days) | 60.2K | ★ 4.6M |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,534,000.00 |
| Revenue This Year | N/A | $215.96 |
| Revenue Next Year | N/A | $319.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.83 | $2.24 |
| 52 Week High | $9.90 | $5.23 |
Technical Indicators
Market Signals| Indicator | DBCA | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 59.19 | 81.19 |
| Support Level | $9.86 | $2.52 |
| Resistance Level | $9.90 | N/A |
| Average True Range (ATR) | 0.01 | 0.43 |
| MACD | 0.00 | 0.16 |
| Stochastic Oscillator | 66.67 | 97.10 |
Price Performance
Historical Comparison DBCA
ABSI
About DBCA D. Boral Acquisition I Corp. Class A Ordinary Shares
D Boral Acquisition I Corp is a blank check company. It is formed as a BVI business company and formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.